Quectel Unveils Versatile Pi Series SBCs to Power Developer Innovation

NUREMBERG, Germany - Tuesday, 10. March 2026 

(BUSINESS WIRE)--Quectel Wireless Solutions, a global end-to-end IoT solutions provider, today announces the launch of its range of Quectel Pi series of single-board computers (SBCs), designed for a broad range of industrial use cases. The portfolio currently includes three compact development platforms - the Quectel Pi M1, L1, and H1 boards - engineered for low power consumption, cost efficiency, and full-stack software support. Designed to accelerate prototyping and product development, they are well suited for embedded applications, IoT solutions, robotics projects, and edge computing deployments.

“We’re delighted to launch the affordable, versatile, open source Quectel Pi series of SBCs to help developers of real IoT projects in areas such as home automation, robotics, sensors and edge computing to achieve their goals,” says Zjelko Maric, Product Development Manager, EMEA, Quectel Wireless Solutions. “It is important to stress that these boards are for industrial use cases, not just the educational sector. We look forward to supporting the developer community at all levels with these highly capable new Quectel Pi boards.”

SBCs are a complete computer on a single printed circuit board (PCB) and comprise the CPU, GPU, memory storage and I/O ports. Versatility is assured thanks to Wi-Fi, Bluetooth, LTE and Ethernet connectivity options and general-purpose input/output pins to support I2C, SPI and UART interfaces. In addition to powerful CPU and GPU capabilities, support for LTE in the Quectel Pi M1 and L1 boards brings new connectivity capabilities to this sector of the market, and the Quectel H1 Pi board opens up edge computing performance for developers including industrial and commercial developers, educators and students, prosumer and home users, tech enthusiasts and developers, and hobbyists and makers.

With dimensions of 68.70mm x 108.94mm x 23.00mm, the Quectel Pi H1 is powered by the Qualcomm QCS6490 processor and offers numerous interfaces, 8GB LPDDR4x and 128GB UFS memory, an Adreno 643 GPU and options to select the Linux, Debian or Ubuntu operating systems. The SBC also supports 2.4GHZ and 5GHz Wi-Fi, Bluetooth 5.0 and gigabit ethernet connectivity.

Also included in the range is the Quectel Pi M1 and L1 boards, both offering LTE Cat 4 connectivity to users. The Pi M1 product is powered by the Qualcomm SM6115 processor and has dimensions of 56mm x 85mm x 23mm. A wide range of interfaces make this board highly compatible with the Raspberry Pi and the needs of that community of developers. This SBC also offers Wi-Fi5, Bluetooth 5.0 and gigabit ethernet as well as LTE Cat 4 and the option of GNSS connectivity. The Quectel Pi M1 also offers 4GB LPDDR4x and 64GB eMMC memory and the option of Linux, Android or Ubuntu operating systems.

The Quectel Pi L1 board features a 64-bit ARM quad-core Qualcomm QCM2290 processor alongside a rich set of interfaces, a 64-bit Adreno 702 GPU and offering 2 GB LPDDR4X* + 32 GB eMMC memory. With dimensions of 56mm x 85mm x 21.66mm, this SBC offers easy compatibility with the Raspberry Pi and offers two SIM interfaces. The Quectel Pi L1 board offers LTE Cat 4, 2.4GHz and 5GHz Wi-Fi, Bluetooth 5.0, and the option of GNSS connectivity. Both the M1 and L1 boards are designed to integrate seamlessly into existing development board ecosystems, enabling straightforward adoption and compatibility with widely used hardware platforms.

About Quectel

Quectel’s passion for a smarter world drives us to accelerate IoT innovation. A highly customer-centric organization, we are a global end-to-end IoT solutions provider backed by outstanding support and services.

With a worldwide team of over 5,800 professionals, we lead the way in delivering end-to-end IoT solutions, spanning cellular, GNSS, satellite, Wi-Fi and Bluetooth modules, high-performance antennas, value-added services and full turnkey offerings including ODM services and system integration.

With regional offices and support across the globe, our international leadership is devoted to advancing IoT and helping build a smarter world.

For more information, please visit: www.quectel.com or LinkedIn

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20260310949640/en/

Permalink
https://www.aetoswire.com/en/news/1003202653739

Contacts

Media contact: media@quectel.com

شركة Andersen تعتزم الإعلان عن النتائج المالية للربع الرابع وعام 2025 بأكمله

سان فرانسيسكو - الأربعاء, 11. مارس 2026

(BUSINESS WIRE)-- ستعلن شركة Andersen Group Inc.‎ (بورصة نيويورك: ANDG) (Andersen)، المزود الرائد للخدمات المستقلة في مجالات الضرائب والتقييم والاستشارات المالية للأفراد والمكاتب العائلية والشركات والصناديق في الولايات المتحدة، عن نتائجها المالية للعام الكامل والربع الرابع من عام 2025 بعد إغلاق السوق يوم الثلاثاء 17 مارس 2026.

سيعمد المدير التنفيذي ورئيس مجلس إدارة شركة Andersen،‏ Mark L. Vorsatz، والمدير المالي لشركة Andersen،‏ Neal Livingston، إلى عقد مؤتمر هاتفي لمناقشة النتائج المالية لشركة Andersen يوم الثلاثاء 17 مارس 2026 الساعة 5 مساءً بتوقيت شرق الولايات المتحدة.

 يمكن للمشاركين الانضمام إلى البث المباشر على الإنترنت على https://event.choruscall.com/mediaframe/webcast.html?webcastid=J3Hvslre. ستتم أرشفة رابط إعادة البث المباشر على موقع علاقات المستثمرين الإلكتروني لشركة Andersen على investor.andersen.com في غضون بضع ساعات بعد الحدث، وسيظل متاحًا على الموقع الإلكتروني لمدة ستة أشهر.

 نبذة عن Andersen

تُعدّ شركة Andersen مزودًا رائدًا للخدمات المستقلة في مجالات الضرائب والتقييم والاستشارات المالية للأفراد والمكاتب العائلية والشركات وصناديق الاستثمار البديلة في الولايات المتحدة. ويستند النهج المتميز لشركة Andersen في خدمة العملاء إلى قيم جوهرية تؤكد على إعمال مبادئ المسؤولية والشفافية وتقديم خدمات مستقلة عالية الجودة بسلاسة. وعلى مستوى العالم، تسجل شركة Andersen حضورها في أكثر من 180 دولة عبر منصتها العالمية التي تضم شركات أعضاء وأخرى متعاونة، وتقدم خدمات الضرائب والخدمات القانونية وخدمات التقييم والاستشارات عبر أكثر من 1,000 موقع، بالاعتماد على ما يزيد على 3,000 شريك و50,000 متخصص.

إن نص اللغة الأصلية لهذا البيان هو النسخة الرسمية المعتمدة. أما الترجمة فقد قدمت للمساعدة فقط، ويجب الرجوع لنص اللغة الأصلية الذي يمثل النسخة الوحيدة ذات التأثير القانوني.

 

الرابط الثابت

https://www.aetoswire.com/ar/news/54440983

جهات الاتصال

 

 Gregory Vistica، المدير الإداري، قسم علاقات المستثمرين

 greg.vistica@andersen.com

For the First Time, Ferring Reports Revenue of Over €2.5 Billion in 2025

 SAINT-PREX, Switzerland -

Ferring's total revenues for 2025 exceeded €2.5 billion, an increase of 10% from 2024, mainly driven by our flagship product Menopur®

Continued ramp-up in the US for Adstiladrin®, our novel gene-based therapy for bladder cancer, confirming its position as Ferring’s second major growth driver

Commitment to sustainability demonstrated by SBTi approval of our targets to reduce greenhouse gas emissions, and by our programme to reduce maternal deaths in low- and lower middle-income countries

 

(BUSINESS WIRE)--Ferring today published its 2025 Annual Report and Sustainability Report. The company achieved total revenues of over €2.5 billion in 2025, an increase of 7% over the previous year at actual exchange rates (AER) and 10% at constant exchange rates (CER). These were mainly driven by our flagship product Menopur® (menotropins for injection) in reproductive medicine, and the ramp-up in the US of our breakthrough gene-based therapy for non-muscle invasive bladder cancer, Adstiladrin® (nadofaragene firadenovec-vncg).

Operating expenses were contained to an increase of €61 million year-on-year (i.e. +5% at AER and +7% at CER), and this includes significant non-recurring items (notably impairment charges and restructuring provisions). Underlying operating expenses remained well-controlled, with increased investments targeted to support the growth of Adstiladrin and other opportunities. Thus, operating profit for the year reached €167 million, a decrease of -€24 million (‑13%) versus the prior year at AER, while remaining flat at CER - with the difference being driven by the weaker US dollar.

Following a focus on improving cash conversion after several heavy investments, free cash flow generation approached neutral despite currency headwinds from the weaker US dollar. This represents a substantial improvement compared to the previous year, and a significant step towards sustainable cash generation.

Jean-Frédéric Paulsen, Chairman of the Board of Directors and Chief Executive Officer, said: “This was a pivotal year as we continued evolving our business to become stronger, more agile and more resilient, and importantly we got back to free cash flow neutral. Moreover, in 2025, we introduced an enterprise model designed to create greater value for patients and customers while supporting sustainable growth. This reflects our long-term commitment to serving patients’ need, and fostering an environment where people can learn, grow and perform at their best.”

Ferring has always conducted business responsibly by seeking to protect the environment, create value for society, and uphold our high standards of ethics and governance. In 2025, we passed a major milestone when our targets for reducing greenhouse gas (GHG) emissions were approved by the Science Based Targets initiative (SBTi). This globally recognised standard ensures corporate goals are aligned with international climate policy. During the year, we succeeded in reducing our Scope 1 and 2 GHG emissions by 4.3% and Scope 3 emissions by 19%.

Access to affordable healthcare is embedded in Ferring’s purpose and strategic priorities. The Project Family™: Safe Birth initiative aims to reduce maternal deaths in low- and lower middle-income countries by enabling wider access to Carbetocin Ferring (carbetocin, room-temperature stable formulation). In 2025, we worked with partners to supply around 1.7 million doses of this life-saving medicine at an affordable access price, while gaining further approvals in seven low- and lower middle-income countries.

About Ferring Pharmaceuticals

Ferring Pharmaceuticals is a privately owned specialty biopharmaceutical group committed to building families and helping people live better lives. We are leaders in reproductive medicine with a strong heritage in gastroenterology and urology and are at the forefront of innovation in uro-oncology gene therapy. Ferring was founded in 1950 and employs more than 7,500 people worldwide. The company is headquartered in Saint-Prex, Switzerland, and has operating subsidiaries in more than 50 countries which market its medicines in over 100 countries.

Learn more at www.ferring.com, or connect with us on LinkedIn, Instagram and YouTube.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20260310378948/en/

Permalink

https://www.aetoswire.com/en/news/54442502

Contacts

 

For more information, please contact

Carine Julen

Senior Manager, Corporate Communications & Public Affairs

carine.julen@ferring.com

 

Forbes 40th Annual World’s Billionaires List

 NEW YORK - Tuesday, 10. March 2026 AETOSWire  

Elon Musk Is World’s Richest Person Ever Recorded

 

(BUSINESS WIRE)--Forbes releases its 40th-annual World’s Billionaires list, the definitive ranking of the planet’s richest people. Wealth surged to unprecedented levels over the past year, with fortunes climbing at a record pace. This year’s list features 3,428 billionaires, the most since the list’s inception in 1987. The world’s wealthiest people are worth a record $20.1 trillion combined, up from $16.1 trillion in 2025.

Elon Musk tops the Billionaires list for the second year in a row and is the richest person ever recorded, worth an estimated $839 billion. His net worth skyrocketed by half of a trillion dollars from last year, thanks to a rise in the value of Tesla, and SpaceX which is aiming to go public in 2026. Musk is the first person ever recorded to reach the $800 billion mark, as he moves toward becoming the world’s first trillionaire.

“It’s the year of the billionaire,” said Chase Peterson-Withorn, Forbes Senior Editor, Wealth. “The planet added more than one billionaire per day over the past twelve months as the AI-powered stock market boom boosted fortunes to previously unimaginable heights.”

Larry Page, cofounder of Google, follows far behind Musk, in the No. 2 spot with an estimated net worth of $257 billion, followed by his cofounder Sergey Brin at No. 3 ($237 billion). Jeff Bezos holds the No. 4 spot ($224 billion) and Mark Zuckerberg ($222 billion) rounds out the top 5.

President Donald Trump’s fortune increased by 27%, to an estimated $6.5 billion, thanks largely to crypto dealings and his New York fraud penalty being thrown out. He ranks No. 645 worldwide.

The 2026 ranking features 390 newcomers, including Dr. Dre; Beyonce Knowles-Carter; and tennis legend Roger Federer.

The United States has more billionaires than any other country, now boasting a record 989.

For the full list, visit: www.forbes.com/billionaires.

About Forbes

Forbes is an iconic global media brand that has symbolized success for over a century. Fueled by journalism that informs and inspires, Forbes spotlights the doers and doings shaping industries, achieving success and making an impact on the world. The Forbes brand reaches more than 140 million people monthly worldwide through its trusted journalism, signature ForbesLive events and 49 licensed local editions in 81 countries.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20260310629058/en/

Permalink

https://www.aetoswire.com/en/news/1003537488

Contacts

Media Contact:

Feryal Nawaz, fnawaz@forbes.com

 

Hyperice Introduces Hypervolt 3 Line: More Powerful, Quieter, and Longer-Lasting Percussion Massage Devices

 IRVINE, Calif. - Tuesday, 10. March 2026

Upgraded Line Includes Redesigned Head Attachments and New Carry Case for an Enhanced Warm-Up and Recovery Experience

 

(BUSINESS WIRE)--Hyperice, a high-performance wellness brand, today announced the global launch of the Hypervolt 3 line, its most advanced percussion massage technology to date. The three-device line features the Hypervolt Go 3 ($149), the Hypervolt 3 ($249), and the Hypervolt 3 Pro ($349) — achieving significant performance upgrades across the board at more accessible price points than industry competitors.

Hyperice has built its reputation over the last 15 years on one guiding principle: elite-level recovery technology designed to help everyone perform and move better, from professional athletes to those preparing for or recovering from the day-to-day grind. The Hypervolt 3 line is the latest proof point of that mission.

“The Hypervolt 3 line represents the best percussion massage technology we’ve ever built,” said Jim Huether, CEO of Hyperice. “We’ve taken everything that made the Hypervolt 2 series one of the most trusted products in wellness and recovery and made significant upgrades, delivering more power, reducing noise, and extending battery life. Whether you’re a professional athlete or an everyday athlete, the Hypervolt 3 line was designed to meet you where you are with the most accessible premium percussion massage gun experience.”

The Hypervolt 3 line enables users to massage away stress and tension, loosen muscle knots, maintain flexibility and range of motion, accelerate warm-up before workouts, and recover quickly after activity.

Every device in the Hypervolt 3 line features fully redesigned head attachments that are 33% larger to cover more surface area during each session. All three devices include a carry case, are TSA-friendly for carry-on travel, and are FSA/HSA-eligible in the U.S. The Hypervolt 3 and Hypervolt 3 Pro each come with the redesigned Heated Head Attachment, combining three levels of heat therapy (109 - 120°F / 42.8 - 48.9°C) with percussion massage. The Hypervolt Go 3 is compatible with the new Heated Head Attachment, sold separately.

Hypervolt Go 3 ($149 / CA$199 / £129 / €149) — For the go-getter

The Hypervolt Go 3 is a lightweight percussion massage gun designed for recovery on the go. Weighing just 1.6 lb (0.73kg) with a slanted ergonomic handle, it has five speeds of percussion and four hours of battery life via USB-C charging. Powered by QuietGlide® technology, it includes two redesigned head attachments for more targeted relief. At $149, the Hypervolt Go 3 delivers pro-level recovery in the most portable package on the market, while also offering longer battery life and more precision control.

Key Features: 5 speeds with digital dial, Hyperice App connectivity, 4-hour battery, 1.6 lb (0.73kg), 45 lbs of stall force. Compatible with new Heated Head Attachment.
What's Included: 2 attachments (flat, wedge), carry case, USB-C cord.
Hypervolt 3 ($249 / CA$329 / £219 / €249) — For the everyday performer

The Hypervolt 3 is more powerful than the Hypervolt 2 with five precision speeds and near-silent operation. A pressure sensor guides intensity, while Bluetooth connectivity enables personalized recovery routines via the Hyperice App. The device weighs 2 lb (0.91kg) and includes five redesigned head attachments, among them the Heated Head Attachment, plus a carry case. Battery life extends up to four hours on an 18V wall charger with international plugs included.

Key Features: 5 speeds with digital dial, pressure sensor, Hyperice App connectivity, 4-hour battery, 2 lb (0.91kg), 60 lbs of stall force.
What's Included: 5 attachments (Heated Head, flat, wedge, fork, cushion), carry case, 18V wall charger.
Hypervolt 3 Pro ($349 / CA$469 / £309 / €349) — For the pro

The Hypervolt 3 Pro is Hyperice's flagship percussion device, built for athletes training at high volume, physical therapists, and anyone whose performance depends on their body recovering. At 2.5 lb (1.1kg), it includes the Heated Head Attachment, a premium carry case, and app connectivity for personalized protocols. The Hypervolt 3 Pro delivers therapist-level deep-tissue pressure trusted by professional sports teams at $349.

Key Features: 6 speeds with digital dial, 70 lbs stall force, whisper-quiet 51 dB, Hyperice App connectivity, 4-hour battery, 2.5 lb (1.1kg).
What's Included: 5 attachments (Heated Head, flat, wedge, fork, cushion), carry case, 18V wall charger.
All three devices introduce key upgrades from the Hypervolt 2 generation: more percussion speeds, longer battery life, quieter operation via patented QuietGlide® technology, and fully redesigned attachments that cover more surface area.

“When we introduce the Hypervolt 3, it will be almost 8 years to the day from when we introduced the first Hypervolt at the 2018 NBA All-Star game in LA,” said Anthony Katz, Hyperice Founder. “A lot has changed since then, but we still believe in developing new products that help passionate people move better. Whether it’s introducing a whole new product category, or evolving an existing product line in our ecosystem, our values haven’t changed: to pursue every product idea with the highest level of thought and care for design and performance. And it’s with that mindset that we introduce the Hypervolt 3 line.”

The Hypervolt Go 3, Hypervolt 3, and Hypervolt 3 Pro are available now at hyperice.com and nike.com as well as Best Buy, Dick’s Sporting Goods, and REI in the U.S.

Images: HERE

About Hyperice

Hyperice is a technology-driven company with a giant mission, to help everyone on Earth move and live better. For more than a decade, Hyperice has led a global movement at the confluence of recovery and wellness, specializing in percussion (Hypervolt line), dynamic air compression (Normatec line), vibration (Vyper and Hypersphere lines), thermal technology (Venom line), contrast therapy (Hyperice X), and Hyperboot collaboration with Nike. Now, as a holistic high-performance wellness brand, Hyperice is designed for all – from the most elite athletes, leagues, and teams to consumers everywhere looking to unlock the best version of themselves to help them do what they love, more. Recognized as one of Fast Company’s Most Innovative Companies and a TIME Best Inventions winner, Hyperice has applied its technology and know-how to industries including fitness, hospitality, healthcare, massage, physical therapy, sports performance, and workplace wellness on a global scale. For more information, visit hyperice.com.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20260310934508/en/


Permalink
https://www.aetoswire.com/en/news/1003202653745

Contacts
Contact
Jack Taylor PR
hyperice@jacktaylorpr.com

 

Andersen Global Expands African Presence with Addition of Bravura

 (BUSINESS WIRE)--Andersen Global strengthens its presence in Africa through a Collaboration Agreement with Bravura, a leading independent tax and financial advisory firm based in South Africa and Namibia.

Founded in 1999, Bravura provides tax and financial advisory solutions to listed and private companies, entrepreneurs, and high-net-worth families across the region. Bravura combines deep financial expertise with an entrepreneurial mindset to deliver tailored strategies that drive value. The firm’s multidisciplinary team provides advisory services in mergers and acquisitions, capital raising, corporate restructuring, and succession planning. Additionally, the firm offers tax and accounting strategy, international tax structuring, global mobility, and exchange control compliance solutions.

“At Bravura, we’re driven to redefine standards and deliver bespoke, results-driven solutions that create lasting value for our clients,” said Ian Matthews, head of business development at Bravura. “Our collaboration with Andersen Global enables us to leverage its expansive platform and build working relationships with professionals globally, who share our unwavering commitment to excellence, integrity, and performance.”

Global Chairman and CEO of Andersen, Mark L. Vorsatz added, “Bravura’s proven track record and forward-thinking approach position them as a valuable addition to our platform. The firm’s deep expertise and knowledge of the local market complement our capabilities in Africa and enhance our ability to deliver seamless, multidisciplinary solutions to clients in the region and globally.”

Andersen Global is an international association of legally separate, independent member firms comprised of tax, legal, and valuation professionals around the world. Established in 2013 by U.S. member firm Andersen Tax LLC, Andersen Global now has more than 50,000 professionals worldwide and a presence in over 1,000 locations through its member firms and collaborating firms.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260310549728/en/

Permalink

https://www.aetoswire.com/en/news/1003202653747

Contacts

Megan Tsuei

Andersen Global

415-764-2700

شركة Kinaxis تضع ثقلها كاملا في الابتكار خلال مؤتمر Kinexions القادم في لاس فيغاس

 

سيجمع المؤتمر السنوي للعملاء قادة سلاسل التوريد العالمية لاستكشاف أحدث الاتجاهات وأفضل الممارسات والتقنيات في التخطيط المدعوم بالذكاء الاصطناعي واتخاذ القرارات والابتكار الفعال

(BUSINESS WIRE)-- تم فتح باب التسجيل رسميًا لمؤتمر Kinexions North America، وهو المؤتمر العالمي الرائد في مجال تنسيق سلاسل التوريد ، والذي تستضيفه شركة .Kinaxis ® Inc (المدرجة في بورصة تورنتو تحت الرمز: KXS). يقام هذا الحدث في الفترة من 1 إلى 3 يونيو في لاس فيجاس، بولاية نيفادا، ويجمع قادة سلسلة التوريد والمبتكرين والممارسين من جميع أنحاء العالم لاستكشاف كيف يمكن للمؤسسات الاستفادة من الاستراتيجيات والتقنيات القائمة على الذكاء الاصطناعي لربط البيانات والأشخاص والقرارات.

بعد عام تميز بتقلبات السوق والمخاطر الجيوسياسية والاضطرابات، سيركز مؤتمر هذا العام على كيفية تمكين التنسيق الذكي لسلسلة التوريد للمؤسسات من تجاوز التخطيط التفاعلي إلى بناء قدرة حقيقية على التكيف المؤسسي. يعد البرنامج بأن يكون مؤتمر Kinexions الأكثر ثراءً واستشرافًا للمستقبل حتى الآن، مع تأكيد مشاركة الكاتب الشهير ورائد الأعمال وخبير الابتكار Peter Hinssen لتقديم كلمة رئيسية متميزة.

 قال Razat Gaurav، الرئيس التنفيذي لشركة Kinaxis: لطالما كان مؤتمر Kinexions هو المكان الذي يجتمع فيه الأفضل في مجال سلاسل الإمداد للمعايرة وتبادل الأفكار، وإعادة التفكير في الممكن وتسريع الابتكار الحقيقي، وعام 2026 سيضع معيارًا جديدًا. ما أسمعه باستمرار من عملائنا هو التحدي المتمثل في اتخاذ قرارات سلسلة التوريد الذكية بمستويات غير مسبوقة من التغيير وعدم اليقين. القادة الذين يمضون قدمًا هم الذين يتبنون التفكير القائم على النتائج ويستفيدون من التنسيق الوكيل المدعوم بالذكاء الاصطناعي. نحن متحمسون للترحيب بمجتمع عملائنا وشركائنا حيث يجتمعون لمدة ثلاثة أيام من التواصل المؤثر والتعلم وتشكيل ما هو قادم".

طوال فترة المؤتمر، سيستمع الحاضرون مباشرة إلى العديد من عملاء Kinaxis، الذين يدير الكثير منهم بعضًا من أكثر سلاسل الإمداد تعقيدًا في العالم، وستتاح لهم الفرصة لرؤية كيفية مساهمة منصة ™Kinaxis Maestro ووكلاء Maestro Agents في تحويل بيئات سلاسل الإمداد اليوم، والتعمق أكثر في كيفية إعادة تشكيل الذكاء الاصطناعي لعملية اتخاذ القرار.

تشمل النقاط الرئيسية لمؤتمر 2026 ما يلي:

 كلمة رئيسية على المنصة من قبل Peter Hinssen، الذي سيشارك منظورًا حصريًا حول كيفية قيام القادة بتحويل عدم اليقين إلى فرص وبناء منظمات جريئة ومستعدة للمستقبل في عالم لا يعرف الاستقرار، وذلك عقب إصدار كتابه الأحدث The Uncertainty Principle.

 مجموعة قوية من المتحدثين من العملاء من بعض سلاسل التوريد الأكثر تعقيدًا وشمولية في العالم.

 العشرات من الجلسات، والتدريب العملي، وورش العمل التقنية المتعمقة، وعروض ابتكار المنتجات المصممة لمساعدة المؤسسات على تسريع اعتماد القيمة.

 جوائز عملاء Kinaxis السنوية، التي تكرم الأفراد والمنظمات الذين يقودون الطريق في الابتكار والتحول والتميز في سلسلة التوريد.

 الوصول إلى إعلانات المنتجات الحصرية، وحفلات الاستقبال للتواصل، وتجربة مجتمع Kinaxis الكاملة.

سيستضيف فندق ذا كوزموبوليتان في لاس فيغاس فعالية Kinexions التي ستوفر خلفية نابضة بالحياة وغامرة للتعلم والتواصل، حيث تمزج بين الفخامة العصرية وطاقة واحدة من أكثر الوجهات شهرة في العالم. سيحظى الحضور بفرصة الاطلاع المبكر على ابتكارات المنصة الجديدة والقدرات الموسعة ضمن منصة Maestro، مما يعزز التزام Kinaxis بتطوير إدارة سلسلة التوريد بما يتجاوز عمليات التخطيط التقليدية.

 التسجيل في Kinexions North America مفتوح الآن على www.kinexions.com.

 لمعرفة المزيد عن Kinaxis ومنصة تنسيق سلسلة التوريد الرائدة في الصناعة، تفضل بزيارة www.kinaxis.com.

 حول Kinaxis

 تعد شركة Kinaxis رائدة في تنظيم سلسلة التوريد الحديثة، وتشغيل سلاسل التوريد العالمية المعقدة، ودعم الأشخاص الذين يديرونها. تجمع منصة Maestro وهي منصة قوية لتنظيم سلسلة التوريد مدعومة بالذكاء الاصطناعي بين التقنيات والأساليب الملكية التي توفر الشفافية الكاملة والمرونة عبر سلسلة التوريد بأكمله، من التخطيط الاستراتيجي متعدد السنوات إلى التسليم في المرحلة الأخيرة. نحظى بثقة العلامات التجارية العالمية الشهيرة لتوفير المرونة والقدرة على التنبؤ اللازمين للتعامل مع التقلبات والاضطرابات التي نشهدها اليوم. لمزيد من الأخبار والمعلومات، ترجى زيارة kinaxis.com أو متابعتنا على LinkedIn.

المصدر: .Kinaxis Inc

 

إن نص اللغة الأصلية لهذا البيان هو النسخة الرسمية المعتمدة. أما الترجمة فقد قدمت للمساعدة فقط، ويجب الرجوع لنص اللغة الأصلية الذي يمثل النسخة الوحيدة ذات التأثير القانوني.

 

الرابط الثابت

https://www.aetoswire.com/ar/news/544422641

جهات الاتصال

 العلاقات الإعلامية

Erin Boyle ‏|‏ Kinaxis

 eboyle@kinaxis.com

  ‎+1 519-574-4065

Kinaxis Goes All-In on Innovation at Upcoming Kinexions in Las Vegas

 

Annual customer conference will bring together global supply chain leaders to explore the latest trends, best practices and technologies in AI-powered planning, decision-making and agentic innovation

(BUSINESS WIRE)--Registration is officially open for Kinexions North America, the premier global supply chain orchestration conference hosted by Kinaxis® Inc. (TSX: KXS). Taking place June 1–3 in Las Vegas, Nevada, the event brings together supply chain leaders, innovators and practitioners from around the world to explore how organizations can leverage AI-driven strategies and technologies to connect data, people and decisions.

After a year defined by market volatility, geopolitical risk and disruption, this year’s conference will focus on how intelligent supply chain orchestration enables organizations to move beyond reactive planning to building true enterprise adaptability. The program promises to be the most immersive and future-forward Kinexions yet, with renowned author, entrepreneur and innovation expert, Peter Hinssen confirmed as a featured keynote address.

“Kinexions has always been the place where the best in supply chain come together to calibrate and share ideas, rethink what’s possible and accelerate real innovation — and 2026 is going to set a new bar,” said Kinaxis Chief Executive Officer, Razat Gaurav. “What I’m hearing consistently from our customers is the challenge of making smart supply chain decisions with unprecedented levels of change and uncertainty. The leaders pulling ahead are the ones embracing outcomes‑driven thinking and leveraging AI‑powered agentic orchestration. We’re excited to welcome our community of customers and partners as they come together for three days of impactful networking, learning, and shaping what’s next.”

Throughout the conference, attendees will hear directly from numerous Kinaxis customers, many of which are operating some of the world’s most complex supply chains, and will have the opportunity to see firsthand how the Kinaxis Maestro™ platform and Maestro Agents are helping to transform today’s supply chain environments and dive further into how AI is reshaping decision making.

Key highlights for the 2026 conference include:

• Mainstage keynote from Peter Hinssen, who will share an exclusive perspective on how leaders can turn uncertainty into opportunity and build bold, future‑ready organizations in a “Never Normal” world, following the release of his latest book ‘The Uncertainty Principle’.
• A robust lineup of customer speakers from some of the world’s most complex and extensive supply chains.
• Dozens of sessions, hands‑on training, deep‑dive technical workshops, and product innovation showcases designed to help organizations accelerate value adoption.
• The annual Kinaxis Customer Awards, recognizing individuals and organizations leading the way in innovation, transformation, and supply chain excellence.
• Access to exclusive product announcements, networking receptions, and the full Kinaxis community experience.

Hosted at The Cosmopolitan of Las Vegas, Kinexions will offer a vibrant and immersive backdrop for learning and connection, blending modern luxury with the energy of one of the world’s most iconic destinations. Attendees will gain early visibility into new platform innovations and expanded capabilities within Maestro, reinforcing the Kinaxis commitment to advance supply chain orchestration beyond traditional planning processes.

Registration for Kinexions North America is open now at www.kinexions.com.

To learn more about Kinaxis and its industry‑leading supply chain orchestration platform visit www.kinaxis.com.

About Kinaxis

Kinaxis is a leader in modern supply chain orchestration, powering complex global supply chains, and supporting the people who manage them. Our powerful, AI-infused supply chain orchestration platform, Maestro, combines proprietary technologies and techniques that provide full transparency and agility across the entire supply chain — from multi-year strategic planning to last-mile delivery. We are trusted by renowned global brands to provide the agility and predictability needed to navigate today’s volatility and disruption. For more news and information, please visit kinaxis.com or follow us on LinkedIn.

Source: Kinaxis Inc.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20260309118533/en/

Permalink

https://www.aetoswire.com/en/news/54442264

Contacts

 

Media Relations

Erin Boyle | Kinaxis

eboyle@kinaxis.com

+1 519-574-4065

Investor Relations

Rick Wadsworth | Kinaxis

rwadsworth@kinaxis.com

613-907-7613

ارتفاع صافي أرباح استثمار القابضة 122% إلى 938 مليون ريال قطري وارتفاع الإيرادات 54% إلى 6.4 مليار ريال قطري بفضل التوسع الدولي

الدوحة, قطر - الثلاثاء, 10. مارس 2026

أداء استثنائي وارتفاع لكافة المؤشرات في نتائجها المالية للسنة المنتهية في 31 ديسمبر 2025

*على أساس سنوي

أعلنت استثمار القابضة ش.م.ع.ق عن نتائجها المالية للسنة المنتهية في 31 ديسمبر 2025، بعد اعتمادها من مجلس إدارة الشركة، مسجلة ارتفاع الإيرادات بنسبة 54% لتبلغ 6.4 مليار ريال قطري مقابل 4.2 مليار ريال قطري في 2024 ، وبلغ إجمالي أرباح الشركة2.1مليار ريال قطري مقابل مليار ريال قطري في 2024 بارتفاع 111%. كما حققت الشركة أرباحاً قبل اقتطاع الفائدة والضريبة والاستهلاك وإطفاء الدين EBITDA بلغت 1.5 مليار ريال قطري بزيادة 102% على أساس سنوي.  وسجلت النتائج ارتفاعاً في صافي أرباح الشركة بنسبة 122% إلى 938 مليون ريال قطري. وقد ارتفع العائد على السهم بنسبة 145% ليصل إلى 0.264 ريال قطري.

يعزى نمو صافي الأرباح بنسبة 122%  إلى ارتفاع إيرادات الشركة، والتي اعتمدت بشكل رئيسي على الإيرادات من قطاعي المقاولات التخصصية والرعاية الصحية. ويعكس هذا النمو قدرة الشركة على تحويل النمو التشغيلي إلى ربحية مستدامة مع الحفاظ على الانضباط المالي.

كما سجلت النتائج المالية لعام 2025 زيادة في الأصول بنسبة 23% عن 2024، ناتجة عن المشاريع الجديدة التي أضافتها استثمار القابضة لمحفظتها مثل مستشفى بغداد الدولي في العراق.

وقد أوصى مجلس إدارة استثمار القابضة بتوزيع أرباح تعادل 20% من رأس المال  بواقع سهمين مجانيين لكل عشرة أسهم.

وأظهرت النتائج تحقيق تحسن ملحوظ في مختلف المؤشرات المالية الرئيسية خلال عام 2025، مدفوعاً بالتوسع في القطاعات الأساسية للشركة، وتحسن وتيرة تنفيذ المشاريع، إلى جانب تعزيز الكفاءة التشغيلية عبر عمليات المجموعة. وتعكس هذه النتائج قدرة استثمار القابضة على توسيع نطاق أعمالها مع الحفاظ تزايد مستويات الربحية.

معلقاً على النتائج، قال خوان ليون - الرئيس التنفيذي لشركة استثمار القابضة:

"يمثل عام 2025 محطة مهمة في مسيرة استثمار القابضة، حيث يعكس الأداء المالي القوي نجاحنا في تنفيذ استراتيجية النمو والتوسع عبر مختلف قطاعات الشركة، إلى جانب الجهود الكبيرة التي تبذلها فرق العمل في مختلف الأسواق.

إن تحقيق نمو قوي في جميع المؤشرات المالية الرئيسية يؤكد متانة نموذج أعمالنا المتنوع وتركيزنا المستمر على التميز التشغيلي  مع الحفاظ على الانضباط المالي ومعايير الحوكمة. ومع استمرارنا في توسيع نطاق أعمالنا وتعزيز حضورنا في الأسواق، سنواصل العمل على تحقيق قيمة مستدامة للمساهمين مع استكشاف فرص جديدة للنمو."

وأضاف ليون: "إن قوة المركز المالي للشركة تتيح لنا المضي قدماً في تنفيذ مبادراتنا الاستراتيجية المقبلة إضافة إلى دراسة فرص محتملة في أسواق رأس المال لدعم المرحلة المقبلة من توسع الشركة."

قادت مجموعة المقاولات التخصصية إسهام القطاعات في إيرادات الشركة خلال العام 2025، وذلك من خلال نشاط المجموعة اللافت محلياً وإقليمياً لاسيما في المملكة العربية السعودية، سوريا، الجزائر، العراق وغيرها. كما شهدت أعمال مجموعة الصناعات والمقاولات التخصصية نمواً ملحوظاً، حيث تقوم المجموعة بتنفيذ مشاريع في 12 دولة. وهي مشاريع كبرى في قطاعاتها مثل مشاريع البحر الأحمر في المملكة العربية السعودية، مشاريع البنية التحتية في سوريا، بالإضافة إلى عدد من المشروعات الهامة في قطر مثل الأبنية التعليمية وغيرها.

وقد استطاعت المجموعة تأمين 262 عقداً جديداً خلال العام، الأمر الذي يعكس الثقة المتزايدة في أداء شركاتها كشريك في تنفيذ كبرى المشروعات.

كما واصلت مجموعة الرعاية الصحية في استثمار القابضة عن طريق شركتها التابعة أبيكس هيلث تحقيق نمو مستدام مدفوعاً بتطبيق نموذج إدارة وتشغيل المستشفيات إقليمياً، منها في العراق وليبيا.  وقد أسهمت مجموعة الرعاية الصحية في زيادة الإيرادات خلال 2025. كما استمرت مستشفيات الشركة داخل قطر؛ مستشفى ذا فيو والمستشفى الكوري في اكتساب مزيد من الثقة عن طريق الالتزام بأعلى معايير الجودة الدولية واستضافة أهم وأبرز الكوادر الطبية العالمية. فقد قامت مستشفى ذا فيو بإجراء أكثر من 100 عملية روبوتية خلال 2025.

تساهم مجموعة الخدمات، وتحديدًا شركات إدارة المرافق وخدمات الطعام، في زيادة إيرادات الشركة وربحيتها بنسبة لافتة، ونجحت شركات المجموعة في الحفاظ على ريادتها خلال العام عبر تحسين الكفاءة التشغيلية، والاستثمار في التكنولوجيا، وتعزيز رضا العملاء، فضلاً عن التوسع في عدة دول إقليميًا وعالميًا. وقد نجحت مجموعة الخدمات في تأمين أكثر من 450 عقداً جديداً خلال 2025، بالإضافة إلى عقودها المستمرة نظراً لقدرة المجموعة اللافتة على الاحتفاظ بالعملاء، بنسبة بلغت 95%. يذكر أن المجموعة تقدم خدمات منها إدارة المرافق، خدمات وحلول الطعام، حلول الأيدي العاملة والموارد البشرية، ومساندة الفعاليات وغيرها.

كما شهد أداء مجموعة التطوير العقاري والمشاريع السياحية في الشركة نمواً في الإيرادات بنسبة 99% عن العام 2024، يعزى إلى الإقبال على مشروعات القطاع، ومنها جزيرة المها، التي زارها خلال 2025 أكثر من5.2 مليون زائر. كما شهد العام ختاماً قوياً للموسم الثالث من مدينة الألعاب العالمية لوسيل وينتر وندرلاند، وانطلاقة ناجحة لموسمها الرابع، حيث استضافت المدينة الآلاف من سكان قطر وزوارها. هذا فضلاً عن مرافق القطاع الفندقية مثل منتجعي كتارا هيلز وميسان الدوحة، الذين استمرا في ريادة مجال الضيافة الراقية في قطر على مدار العام.

أما عن مشاريع المجموعة خارج قطر، فتتقدم عملية إنشاء فندق وشقق ريكسوس بغداد، مع تزايد عمليات البيع وتزايد الطلب على الشراء. بالإضافة إلى مشروع منتجع روزوود المالديف الذي شهد تطوراً متسارعاً من حيث معدل الإنجاز لإتمام المشروع المتوقع أن يتصدر المشهد السياحي في جزر المالديف والعالم.  

الرابط الثابت

https://www.aetoswire.com/ar/news/1003202653751

جهات الاتصال

Nesrine Nacef

Corporate Communications Manager

0097466157504

Estithmar Holding Net Profit Surges 122% to QAR 938 Million; Revenue Rises 54% to QAR 6.4 Billion for the Year Ended 31 December 2025

Doha, Qatar - Tuesday, 10. March 2026

- Sustainable Growth Driven by International Expansion

- Significant Increase Across Key Metrics

Estithmar Holding Q.P.S.C. has announced its financial results for the year ended 31 December 2025. The group reported a 54% increase in revenue to QAR 6.4 billion, compared with QAR 4.2 billion in 2024. Gross profit rose to QAR 2.1 billion, up from QAR 1 billion in 2024, representing growth of 111%. EBITDA reached QAR 1.5 billion, an increase of 102% year-on-year.

Net profit climbed 122% compared with 2024, reaching QAR 938 million. Earnings per share increased by 145% to QAR 0.264.

The growth in net profit was primarily driven by higher revenues, particularly from the specialized contracting and healthcare sectors. The results reflect the group’s ability to convert operational growth into sustainable profitability while maintaining financial discipline.

Total assets increased by 23% in 2025 compared with the previous year, largely due to new projects added to Estithmar Holding’s portfolio, including Baghdad International Hospital in Iraq.

The Board of Directors has recommended the distribution of dividends equivalent to 20% of the company’s share capital, in the form of 2 bonus shares for every 10 shares held.

The 2025 results show a marked improvement across key financial indicators, supported by expansion in the group’s core sectors, improved project execution, and enhanced operational efficiency across its businesses. These results demonstrate Estithmar Holding’s ability to scale its operations while maintaining financial discipline and strengthening profitability.

Commenting on the results, Juan Leon, Holding Chief Executive Officer of Estithmar Holding, said: “2025 represents an important milestone in Estithmar Holding’s journey. Our strong financial performance reflects the successful execution of our growth and expansion strategy across the group’s sectors, as well as the considerable efforts of our teams across multiple markets.

“Achieving strong growth across all key financial indicators highlights the resilience of our diversified business model and our continued focus on operational excellence, maintaining financial discipline and governance. As we expand our footprint and strengthen our presence in regional markets, we remain committed to delivering sustainable value to shareholders while exploring new growth opportunities.”

“The group’s strong financial position allows us to move forward with upcoming strategic initiatives, while also evaluating potential opportunities in capital markets to support the next phase of the group’s expansion”, Leon added.

The specialized contracting group accounted for the largest share of revenue contribution in 2025. The sector delivered strong activity both locally and regionally, particularly in Saudi Arabia, Syria, Algeria and Iraq. During the year, the industrial and specialized contracting businesses continued to expand, executing major projects across 12 countries. These include large-scale developments such as the Red Sea projects in Saudi Arabia, infrastructure projects in Syria, and several major developments in Qatar, including educational facilities.

During the year, the group secured 262 new contracts, reflecting growing confidence in its companies as partners for the delivery of major projects.

Estithmar Holding’s healthcare group, through its subsidiary Apex Health, also continued to deliver sustainable growth, driven by the implementation of its regional hospital management and operations model, including in Iraq and Libya.

Within Qatar, the group’s hospitals; The View Hospital and the Korean Medical Center continued to build patient trust through adherence to the highest international quality standards and by hosting leading global medical professionals. In 2025, The View Hospital performed more than 100 robotic surgeries.

Read more  

Permalink

https://www.aetoswire.com/en/news/1003202653750

Contacts

Nesrine Nacef

Corporate Communications Manager

0097466157504

Speechmatics Achieves a World First in Bilingual Voice AI with New Arabic–English Medical Model

 

 The new industry-leading bilingual model includes the world's first Arabic–English bilingual medical model, achieving 6.3% WER on mixed-speech benchmarks and 35% fewer errors than the nearest competitor.

 

(BUSINESS WIRE)--Speechmatics today launched its new Arabic–English bilingual model, a single production-ready model that handles Arabic dialects and English simultaneously. It can be deployed on-premises and on-device, supports speaker diarization and speaker focus, and runs across real-time and batch workflows.

As part of the rollout, Speechmatics introduces the world's first Arabic–English bilingual medical model: a specialized clinical variant trained on twice the vocabulary of its English Medical Model, built to ensure that patient records are always accurate and up to date.

Code-switching: going beyond monolingual AI

A doctor names a drug in English then switches back to Arabic. A Gulf contact center agent shifts registers without thinking. A finance officer moves across both languages in a single sentence. Across MENA, this is Monday morning.

Monolingual models weren't built for this. When a speaker shifts between Arabic and English mid-sentence, the model loses the thread - misattributing words, dropping terminology, or simply getting it wrong. In a contact centre or a clinical setting, that's not an edge case. It's the norm.

Our model, tailored to support both languages, resolves this issue, with speaker diarization and speaker focus ensuring every word is attributed to the right person throughout.

In new benchmarking, Speechmatics achieves a 35% lower Word Error Rate than Google on Arabic–English code-switching tasks (6.3% vs 9.7%), making it the most accurate code-switching model available

Dialect coverage that clears the field

Arabic carries distinct vocabulary, phonology, and rhythm across the region, including Gulf, Egyptian and Levantine dialects. Models trained on broadcast Modern Standard Arabic struggle the moment a real conversation starts.

Speechmatics leads major providers on Arabic-only transcription, delivering 24% lower Word Error Rate than Google (4.5% vs 5.9%) and outperforming OpenAI Whisper, AssemblyAI, Deepgram, Amazon, and Microsoft.

Built for enterprise deployment

Data sovereignty is a hard requirement across MENA, with regional data protection legislation in Saudi Arabia, the UAE, and beyond placing strict obligations on where voice data is processed and stored. Speechmatics meets this directly.

The model deploys across cloud SaaS, on-premises, and on-device, powered by NVIDIA AI infrastructure and optimized through NVIDIA Dynamo-Triton for high-throughput, low-latency processing at scale. Sub-second latency is maintained across all deployment modes.

Real-time streaming and batch transcription run on the same model, removing the accuracy trade-off that typically comes with switching between the two. Speaker diarization, speaker focus, punctuated transcripts, and timestamped outputs are included as standard.

The world's first bilingual medical model

In clinical environments across MENA, English drug names, procedures, and dosages appear constantly inside Arabic speech. Generic models mishandle them, and those errors can land in the patient record.

Trained on twice the vocabulary of Speechmatics' English Medical Model, incorporating both English and Arabic clinical terminology, real dialect variation, and speech from actual clinical settings, the world's first Arabic–English bilingual medical model accurately transcribes ICD-10-CM codes, drug names, dosages, and clinical shorthand regardless of which language carries them. On-premises and on-device deployment make it viable for the regulated environments where clinical AI is increasingly being built across the region.

“This was critical to achieving meaningful outcomes for customers across the region who kept describing the same challenge. In a Cairo hospital or a Riyadh contact center, Arabic and English flow concurrently - the drug name arrives in English, the rest of the sentence is Arabic. Delivering significant impact meant removing that friction from voice interactions. We trained on real voices, real dialects and real clinical vocabulary - because that’s the only way to build something that truly works where it’s used.” - Katy Wigdahl, CEO, Speechmatics

"We ran extensive evaluations on complex clinical audio, including code-switching and dialect-heavy consultations common across MENA. Speechmatics' bilingual medical model was the only one that met the performance thresholds we require to maintain high-quality clinical documentation as we scale regionally. That alignment made the partnership a strong fit for our expansion." - Patrick Nguyen, Head of Engineering, MENA, Sully.ai

Both models are available now. Visit speechmatics.com for access and deployment options.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20260310752540/en/

Permalink

https://aetoswire.com/en/news/1003202653744

Contacts

Media Contact: Mieke Smith Communications & Content Lead, Speechmatics mieke.smith@speechmatics.com

Corpay Cross-Border Named Official Foreign Exchange Provider of the ABB FIA Formula E World Championship

  

Delivering exclusive commercial FX solutions to the world’s premier all-electric racing series

(BUSINESS WIRE)--Corpay, Inc.*, (NYSE: CPAY) a global leader in corporate payments, today announced that its Cross-Border business has partnered with Formula E, the world’s first all-electric FIA World Championship and B Corp Certified sport. Under the agreement, Corpay becomes the exclusive and Official Foreign Exchange Provider of the ABB FIA Formula E World Championship.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260310640540/en/

The ABB FIA Formula E World Championship brings dramatic racing to the heart of some of the world’s most iconic cities providing an elite motorsport platform for the world’s leading automotive manufacturers to accelerate electric vehicle innovation with the GEN3 Evo race continuing to set a new benchmark as the fastest-accelerating FIA single-seater, rocketing from 0-60 mph in an astonishing 1.82 seconds.

Through this partnership, Corpay Cross-Border will provide comprehensive FX risk management and international payment solutions to support Formula E’s global operations. With races spanning major cities across multiple continents, Formula E operates in a highly dynamic, multi-currency environment — creating a strong strategic fit for Corpay’s expertise in managing foreign exchange exposure and cross-border transactions.

“As a truly global motorsport platform, Formula E operates across numerous currencies and jurisdictions throughout its racing calendar,” said Brad Loder, Chief Marketing Officer, Corpay Cross-Border Solutions. “We are proud to partner with an innovative, forward-thinking championship and to support its international growth with tailored FX and cross-border payment solutions that help mitigate currency risk and drive operational efficiency.”

"Formula E is at the forefront of technology and sustainability, and it is vital that our partners reflect that same forward-thinking approach,” said Max Adkins, Chief Financial Officer, Formula E. “Partnering with Corpay allows us to streamline our global financial operations across a highly dynamic, multi-currency environment. We look forward to working together as we continue to bring the excitement of all-electric racing to fans around the world."

About Corpay

Corpay, Inc. (NYSE: CPAY) is a global S&P500 corporate payments company that helps businesses and consumers pay expenses in a simple, controlled manner. Corpay’s suite of modern payment solutions help its customers better manage vehicle-related expenses (such as fueling and parking), travel expenses (e.g. hotel bookings) and payables (e.g. paying vendors). This results in our customers saving time and ultimately spending less. Corpay Cross-Border refers to a group of legal entities owned and operated by Corpay, Inc.

Corpay – Payments made easy. To learn more visit www.corpay.com.

About Formula E

The ABB FIA Formula E World Championship is known as the next evolution of motorsport. As the world’s first all-electric series, Formula E operates as a high-speed ‘living laboratory’ where innovation and adrenaline collide.

The championship has achieved the milestone of 150 races, and serves as a vital test bed for the world’s leading automotive manufacturers - including Porsche, Jaguar, Nissan, Stellantis, Mahindra and Lola Cars - to innovate and refine the electric vehicle (EV) technologies that will define future urban mobility.

Underpinning this performance is a profound commitment to impact. Formula E is a Certified B Corp - the world’s first and only sport to achieve this designation - reflecting its dedication to high standards of social and environmental transparency. It also stands as the only sport in the world to be Net Zero Carbon since inception and recently became the first to achieve the BSI Net Zero Pathway certification, setting a new global benchmark for science-based climate action.

As a progressive challenger in the sports landscape, Formula E is defined by unpredictable, wheel-to-wheel competition. In 11 seasons, the series has crowned 10 different champions, proving it to be one of the most competitive and open titles in world championship level sport. With a commitment to accessibility and a grid of world-class drivers and manufacturers, the series continues to rewrite the rules of elite sport, engaging a new generation who value purposeful ambition and fearless action.

www.FIAFormulaE.com

For Formula E media enquiries, please contact media@fiaformulae.com.

About ABB:

ABB is a global technology leader in electrification and automation, enabling a more sustainable and resource-efficient future. By connecting its engineering and digitalization expertise, ABB helps industries run at high performance, while becoming more efficient, productive and sustainable so they outperform. At ABB, we call this ‘Engineered to Outrun’. The company has over 140 years of history and more than 110,000 employees worldwide. ABB’s shares are listed on the SIX Swiss Exchange (ABBN) and Nasdaq Stockholm (ABB). www.abb.com

*“Corpay” in this document primarily refers to the Cross-Border Division of Corpay, Inc. https://www.corpay.com/cross-border; a full listing of the companies that are part of Corpay Cross-Border is available here: https://www.corpay.com/compliance.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20260310640540/en/

Permalink

https://aetoswire.com/en/news/1003202653743

Contacts

Corpay Contact:

Brad Loder

Chief Marketing Officer

Corpay Cross-Border Solutions

+1 (647) 627-6635

brad.loder@corpay.com

 

TTNE تعلن عن جائزة الساونا العالمية "SAUNA37 2026"

 طوكيو - الثلاثاء, 10. مارس 2026 أيتوس واير

 

(BUSINESS WIRE)-- أعلنت اليوم شركة .TTNE Inc عن جائزة "SAUNA37 2026"، وهي جائزة الساونا العالمية التي تمنح تقديرًا لـ 37 وجهة ساونا حول العالم.

من خلال هذه المبادرة، نهدف إلى المساهمة في النمو العالمي لثقافة الساونا وخلق مستقبل حيث يمكن للناس في جميع أنحاء العالم أن يعيشوا حياة أكثر سعادة وصحة من خلال الساونا.

تأسست TTNE على يد Totonoe Oyakata (المعروف بـ Dai Matsuo) وSauna Master (المعروف بـ Daisuke Akiyama)، اللذين اختبرا بأنفسهما مجموعة من أفضل مرافق الساونا في العالم. أدت رغبتهم في إنشاء ثقافة ساونا متجذرة في اليابان إلى إنشاء TTNE.

نظرًا لأن الناس لديهم الفرصة مرة أخرى لاستكشاف تجارب الساونا في جميع أنحاء العالم، تهدف SAUNA37 إلى تقديم مرافق وثقافات الساونا المتنوعة والفريدة في جميع أنحاء العالم. من خلال هذه المبادرة، نسعى إلى تطوير ثقافة الساونا اليابانية مع مشاركتها أيضًا مع العالم.

تظل TTNE ملتزمة بالتطور العالمي لثقافة الساونا، وتعمل باستمرار على إلهام وتعزيز نموها في جميع أنحاء العالم.

 SAUNA37

 https://www.sauna37.com/

  - تم ترشيح 37 منشأة ساونا -

38° THE BATHHOUSE (أستراليا)

Adventuremine (السويد)

Allas Pool (فنلندا)

Aquardens Verona Spa (إيطاليا)

ARC (المملكة المتحدة)

Arctic Bath (السويد)

Biome by Corinthia London (المملكة المتحدة)

Blue Lagoon Iceland (آيسلندا)

Capybara Bathing (أستراليا)

Chochołowskie Termy (بولندا)

Great Jones Spa (الولايات المتحدة الأمريكية)

Hotel Jungbrunn (النمسا)

Hotel Krallerhof (النمسا)

Hotel Tjampuhan and Spa (إندونيسيا)

KAN NO JIGOKU RYOKAN (اليابان)

KEDR Spa & Sauna (تايلاند)

Kokyu no Ma, Shiriuchi Onsen (اليابان)

Les Bains de Lavey (سويسرا)

Lonna Sauna (فنلندا)

Nowhere Baths (سنغافورة)

OCHIAIRO (اليابان)

Rudas Thermal Bath (المجر)

SATAMA Sauna Resort & Spa (ألمانيا)

Scandinave Spa Whistler (كندا)

Sense Of Self (أستراليا)

Serlachius Art Sauna (فنلندا)

Soak Bathhouse - South Yarra (أستراليا)

Soria Moria Sauna (النرويج)

SPA ONE (هولندا)

Strøm Nordic Spa (كندا)

Széchenyi Thermal Bath and Swimming Pool (المجر)

Tamina Therme (سويسرا)

Terme Olimia (سلوفينيا)

Thermen Maarssen (هولندا)

Tupaswilla (فنلندا)

V Spa Hotel and Conference Centre (إستونيا)

Vabali Spa Hamburg (ألمانيا)

 TTNE

 الموقع الرسمي وInstagram

 TTNE: ‏‏ https://ttne.jp @ttne_official

SHOP TTNE: ‏‏ https://www.ttne.shop

SAUNA SELECT: ‏‏ https://sauna-select.com

SAUNACHELIN: ‏‏ https://www.saunachelin.com @saunachelin_official

SAUNA37: ‏‏ http://sauna37.com @sauna37_official

HARVIA: ‏‏ https://www.harvia.com, https://harvia.jp, @harviaglobal, @harvia.jp

إن نص اللغة الأصلية لهذا البيان هو النسخة الرسمية المعتمدة. أما الترجمة فقد قدمت للمساعدة فقط، ويجب الرجوع لنص اللغة الأصلية الذي يمثل النسخة الوحيدة ذات التأثير القانوني.

صور / وسائط متعددة متوفرة على : https://www.businesswire.com/news/home/20260308149186/en

الرابط الثابت

https://www.aetoswire.com/ar/news/544417891

جهات الاتصال

 .TTNE Inc

 contact@ttne.jp

TTNE Announces the World Sauna Award “SAUNA37 2026”

 TOKYO - Tuesday, 10. March 2026 AETOSWire 

(BUSINESS WIRE)--TTNE Inc. today announced “SAUNA37 2026”, the world sauna award recognizing 37 sauna destinations worldwide

Through this initiative, we aim to contribute to the global growth of sauna culture and create a future where people around the world can lead happier and healthier lives through saunas.

TTNE was founded by Totonoe Oyakata (Dai Matsuo) and Sauna Master (Daisuke Akiyama), who have personally experienced some of the world's finest saunas. Their desire to establish a similar deep-rooted sauna culture in Japan led to the creation of TTNE.

As people once again have the opportunity to explore sauna experiences around the world, SAUNA37 aims to introduce the diverse and unique sauna facilities and cultures across the globe. Through this initiative, we seek to further evolve Japan’s sauna culture while also sharing it with the world.

TTNE remains committed to the global evolution of sauna culture, continuously working to inspire and promote its growth worldwide.

SAUNA37

https://www.sauna37.com/

- Nominated 37 sauna facilities -

38° THE BATHHOUSE (Australia)

Adventuremine (Sweden)

Allas Pool (Finland)

Aquardens Verona Spa (Italy)

ARC (UK)

Arctic Bath (Sweden)

Biome by Corinthia London (UK)

Blue Lagoon Iceland (Iceland)

Capybara Bathing (Australia)

Chochołowskie Termy (Poland)

Great Jones Spa (USA)

Hotel Jungbrunn (Austria)

Hotel Krallerhof (Austria)

Hotel Tjampuhan and Spa (Indonesia)

KAN NO JIGOKU RYOKAN (Japan)

KEDR Spa & Sauna (Thailand)

Kokyu no Ma, Shiriuchi Onsen (Japan)

Les Bains de Lavey (Switzerland)

Lonna Sauna (Finland)

Nowhere Baths (Singapore)

OCHIAIRO (Japan)

Rudas Thermal Bath (Hungary)

SATAMA Sauna Resort & Spa (Germany)

Scandinave Spa Whistler (Canada)

Sense Of Self (Australia)

Serlachius Art Sauna (Finland)

Soak Bathhouse - South Yarra (Australia)

Soria Moria Sauna (Norway)

SPA ONE (Netherlands)

Strøm Nordic Spa (Canada)

Széchenyi Thermal Bath and Swimming Pool (Hungary)

Tamina Therme (Switzerland)

Terme Olimia (Slovenia)

Thermen Maarssen (Netherlands)

Tupaswilla (Finland)

V Spa Hotel and Conference Centre (Estonia)

Vabali Spa Hamburg (Germany)

TTNE

Official site & Instagram

TTNE: https://ttne.jp @ttne_official

SHOP TTNE: https://www.ttne.shop

SAUNA SELECT: https://sauna-select.com

SAUNACHELIN: https://www.saunachelin.com @saunachelin_official

SAUNA37: http://sauna37.com @sauna37_official

HARVIA: https://www.harvia.com, https://harvia.jp, @harviaglobal, @harvia.jp

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20260308149186/en/

Permalink

https://www.aetoswire.com/en/news/54441789

Contacts

 

TTNE Inc.

contact@ttne.jp

WHOOP Broadens WHOOP Advanced Labs Offering, Announcing a Women’s Health Specialized Blood Biomarker Panel

 BOSTON - 

WHOOP deepens investment in women’s physiology with clinically meaningful lab testing, predictive symptom modeling, and new Menstrual Cycle White Paper

 

(BUSINESS WIRE)--WHOOP, the human performance company, today unveiled multiple initiatives and new clinically-backed features, including the coming launch of the company’s Women's Health Specialized Blood Biomarker Panel. Building on the WHOOP Advanced Labs Baseline Panel launched last year, the Women’s Health Specialized Blood Biomarker Panel adds 11 clinically backed, female-specific blood biomarkers that expand insight into areas that are frequently under-measured or misinterpreted in traditional women’s health testing. WHOOP has also announced a new Hormonal Symptom Insights and Predictions update, along with a comprehensive Menstrual Cycle White Paper detailing the science behind its cycle modeling.

These initiatives reflect the company’s commitment to advancing women’s health in an area that has historically been under-researched and underrepresented in data, clinical standards, and performance science. Women represent a growing share of new WHOOP members, with 150% year-over-year growth, signaling increasing demand for health insights that account for hormonal dynamics, training response, and long-term health outcomes. Women also engage with WHOOP AI approximately 30% more than male members, reflecting strong demand for intelligent, personalized women’s health support.

“Unlike solutions that focus on isolated conditions or single life stages, WHOOP delivers a connected health experience informed by one of the world’s largest datasets on women’s physiology,” said Alex Vannoni, Head of Healthcare Product at WHOOP. “We’re not just helping women track their cycles. We’re helping them understand how their physiology evolves over time - and giving them tools to act on it.”

WHOOP Advanced Labs: Women’s Health Specialized Panel

The Advanced Labs baseline and new Women’s Health Specialized Panel create a progressive, female-first testing pathway that supports women across all life stages.

The new panel, launching next month, includes critical biomarkers that dive deeper into cycle regulation and hormonal transitions, including perimenopause, thyroid function, nutrient sufficiency, and bone–metabolic resilience. The biomarkers tested are: Anti-Müllerian Hormone (AMH), Progesterone, Prolactin and Thyroid Peroxidase Antibodies (TPOAb), Free T4, Free T3, Leptin, Vitamin B12 (Cobalamin), Folate, Magnesium and Phosphate (as Phosphorus).

By layering lab data on top of continuous wearable metrics and AI-modelling, WHOOP enables members to see how biomarkers correlate with recovery trends, strain tolerance, sleep efficiency, and stress patterns over time - turning static lab results into dynamic insight.

Members will be able to purchase the Women’s Health Specialized Panel via the WHOOP app.

Hormonal Symptom Insights and Predictions

WHOOP is also expanding its Menstrual Cycle Insights and Pregnancy Insights offering, with a new update - Hormonal Symptom Insights and Predictions. Within the WHOOP app, menstruating members will now receive a personalized model of their cycle that adapts over time, based on their unique physiological data and historical patterns.

Within the WHOOP app, members will now have access to key data about their cycle that allows them to accurately adjust their daily routines, fitness regimes, and recovery practices and anticipate potential symptoms rather than simply recording them. This includes access to:

A dynamic date window for the next period, allowing for more anticipation around the menstrual cycle

Tracked trends in cycle length, period length, and variability, flagging irregular patterns before larger issues persist

Analyzed individual symptom patterns to anticipate when symptoms are most likely to occur

As part of the latest Cycle Insights updates, the feature now integrates with WHOOP Advanced Labs. This integration enables WHOOP to deliver personalized biomarker ranges - categorized as ‘optimal,’ ‘sufficient,’ or ‘out of range’ - based on where a member is in their cycle. When a member completes a blood draw, WHOOP automatically applies the appropriate reference range aligned to their recorded cycle phase, ensuring results are interpreted through the lens of their physiology. It’s another example of how women’s unique biology is embedded into every WHOOP product and feature.

Menstrual Cycle White Paper

WHOOP has also published a comprehensive Menstrual Cycle White Paper outlining the research, methodology, and validation behind its modeling approach. The white paper proves how continuous physiological monitoring improves prediction accuracy over time, how the system accounts for variable cycles, perimenopause, and hormonal birth control, and how prediction windows dynamically widen or narrow based on variability.

By bringing continuous, longitudinal visibility to cycle patterns, WHOOP aims to increase health literacy and close a long-standing data gap in women’s health.

“What makes this powerful isn’t any single data point - it’s how the system comes together," said Emily Capodillupo, Senior Vice President of Research, Algorithms, and Data at WHOOP. “Women don’t experience their physiology in silos. Hormones influence sleep, sleep affects recovery, and recovery shapes training response. By modeling these interactions over time - across continuous biometrics, lab data, and behavior - we can deliver guidance that reflects the full system, not just a snapshot.”

With the support of the WHOOP Medical Advisory Board, including Dr. Robin Berzin and Dr. Hazel Wallace, and in tandem with their recent collaboration with Clue, a leader in menstrual and reproductive health, WHOOP will continue to drive innovation in women’s health and deliver on the company’s goal of adding one billion healthy years to the planet.

The Women’s Health Specialized Panel, along with additional blood panels, will be available via WHOOP in April. You can find links to imagery in our Digital Press Kit.

*The Women’s Health Specialized Panel will be available exclusively in the US at launch.

About WHOOP:

WHOOP delivers a wearable membership to help people live healthier, longer lives and unlock extraordinary potential. Through a powerful 24/7 wearable with a 14-day battery life, WHOOP provides intelligent health guidance across sleep, recovery, strain, fitness, and long-term wellbeing. The health platform includes an FDA-cleared ECG, a Healthspan longevity feature, Blood Pressure Insights, and Advanced Labs blood biomarker analysis. Peer-reviewed research shows: that members who wear WHOOP daily increase their weekly exercise by more than 90 minutes, gain over two hours of additional sleep per week, and improve heart rate variability by 10%.

Trusted by millions of members worldwide including athletes, global leaders, military operators, executives, and artists, WHOOP has become a modern symbol of disciplined, intentional living. WHOOP was founded in 2012 and is headquartered in Boston. The company has raised more than $400 million in venture capital, ships to 56 countries, and operates in six languages. Learn more at whoop.com and connect with WHOOP on Instagram, LinkedIn, X, Facebook, and YouTube.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20260310966566/en/

Permalink

https://aetoswire.com/en/news/54439889

Contacts

 

Taylor (Georgeson) Bonner

whoop@jacktaylorpr.com

Jack Taylor Worldwide

Galderma Introduces Cetaphil AM/PM Antioxidant Serums, a New Science-Driven Defense and Recovery System for Sensitive Skin

 ZUG, Switzerland -

Cetaphil’s new AM/PM Serums are powered by unique Gallic-AOX Power™ Technology, a patent-pending antioxidant complex clinically designed to sync to your skin’s circadian rhythm and support skin resilience

Delivers advanced antioxidant protection by day1 and accelerated repair by night, with visible results in as little as 7 days2

In global testing, Gallic Acid demonstrated 2x greater antioxidant efficacy than Vitamin C3

Co-developed with dermatologists and rigorously tested for sensitive skin to deliver high performance without compromising tolerance

 

(BUSINESS WIRE)--Galderma (SIX: GALD) today announced Cetaphil, the dermatologist-recommended brand trusted by millions with sensitive skin, is launching its new Cetaphil AM/PM Antioxidant Serums, a breakthrough daily system clinically designed to defend skin by day and support accelerated repair by night for sensitive, stressed skin.

While antioxidant serums are a cornerstone of modern skincare, the category has largely been developed without sensitive skin in mind. Despite rapid growth, many formulations prioritize potency over skin compatibility, narrowing options for those who require both efficacy and tolerance. This gap is especially significant given that, globally, an estimated 78% of people report experiencing skin sensitivity4, according to research from Galderma’s Global Sensitive Skincare Faculty (GSSF). Further Galderma research demonstrates that sensitive skin exhibits 16% higher oxidative stress compared to non-sensitive skin under modern environmental conditions5. Together, these findings underscore the need for solutions designed to meet the needs of sensitive skin across ages, environments, and lifestyles.

Cetaphil’s AM/PM Antioxidant Serums were developed to address this unmet need, introducing a new approach that pairs advanced antioxidant science with formulations specifically engineered for sensitive skin, delivering performance without compromising barrier health.

Breakthrough antioxidant technology designed for sensitive skin

At the core of Cetaphil’s AM/PM Antioxidant Serums is a unique Gallic-AOX Power™ Technology, a proprietary antioxidant complex that redefines what antioxidant care can look like for sensitive skin. Combining Gallic Acid and Vitamin E, this advanced technology neutralizes free radicals more efficiently than traditional antioxidants like vitamin C, helping sensitive skin defend itself against oxidative stress without triggering irritation.

In global laboratory testing, Gallic Acid demonstrated more than twice the antioxidant efficacy of Vitamin C3, establishing a new benchmark in antioxidant performance. In global clinical evaluations, consistent use of the AM/PM system resulted in skin that is up to 7x stronger against daily stressors6, reinforcing the role of targeted antioxidant care in supporting barrier health for sensitive skin.

The technology builds on emerging research linking oxidative stress, lifestyle factors, and barrier disruption to periods of heightened skin sensitivity, and is further supported by new research published in collaboration with Galderma’s Global Sensitive Skincare Faculty (GSSF), reinforcing the connection between oxidative stress and sensitive skin.

Each formula was co-developed with dermatologists and clinically tested on sensitive skin to ensure both efficacy and long-term tolerability. This science-led approach reflects Cetaphil’s continued focus on aligning advanced efficacy with the unique needs of sensitive skin.

 

“Sensitive skin experiences oxidative stress just like all skin types; the difference is how it responds. With the Cetaphil AM/PM Antioxidant Serums, we focused on developing an antioxidant system that supports sensitive skin, aligning protection and repair with the skin’s natural daily rhythm. This launch reflects our continued commitment to advancing sensitive skin science through clinically driven innovation”

 

BILL ANDRIOPOULOUS

HEAD OF GLOBAL MEDICAL AFFAIRS GALDERMA

 

Dermatologists increasingly recognize oxidative stress as a key contributor to skin sensitivity and barrier disruption.

 

"In clinical practice, sensitive skin patients are often told to avoid antioxidant products altogether because many formulas can be difficult to tolerate. What makes this formula so impressive is its breakthrough antioxidant technology: Gallic-AOX Power™, a unique combination of gallic acid and vitamin E that helps counteract oxidative stress. With consistent use, the skin can become visibly stronger and more resilient to daily aggressors to improve overall skin quality”

 

DR. AARON FARBERG

DERMATOLOGIST AND MOHS SURGEON, BAYLOR SCOTT & WHITE HEALTH (U.S.)

 

A new approach to antioxidant care for sensitive skin

Environmental aggressors, lifestyle stress, and overuse of active ingredients can contribute to oxidative stress, weakening the skin barrier and intensifying sensitivity. While oxidative stress affects all skin types, sensitive skin often responds with heightened inflammation, making daily antioxidant care both essential and difficult to tolerate.

Cetaphil’s AM/PM Antioxidant Serums were developed as a complementary day-and-night system, formulated to work in sync with the skin’s natural daily rhythm:

AM Advanced Defense Serum helps defend against daily environmental stressors, including pollution, stress and blue light, while strengthening the skin barrier to leave skin visibly more resilient – powered by niacinamide and triple hyaluronic acid to help hydrate, soothe, and support skin barrier health.

PM Repair & Renew Serum supports overnight recovery, helping to repair the skin barrier and address accumulated damage to restore the appearance of stressed, sensitive skin, delivering 2x faster skin barrier repair overnight7 and visibly plumper, more even-looking skin in as little as seven days8 – with hyaluronic acid, pro-vitamin B5, cica, and bifida ferment to help hydrate, soothe, and support skin recovery.

About Cetaphil®

Over seventy-five years ago, a leading pharmacist created the first Cetaphil product – a gentle, yet powerful formula that would clean without stripping and moisturize without clogging. Today, Cetaphil is a dermatologist recommended sensitive skincare brand and is recognized around the world. With the help of leading global skincare experts, they continue to develop innovative skincare technologies for sensitive skin that help restore, protect and maintain skin's health every day. For more information, visit www.cetaphil.com.

About Galderma

Galderma (SIX: GALD) is the pure-play dermatology category leader, present in approximately 90 countries. We deliver an innovative, science-based portfolio of premium flagship brands and services that span the full spectrum of the fast-growing dermatology market through Injectable Aesthetics, Dermato-logical Skincare and Therapeutic Dermatology. Since our foundation in 1981, we have dedicated our focus and passion to the human body's largest organ – the skin – meeting individual consumer and patient needs with superior outcomes in partnership with healthcare professionals. Because we understand that the skin we are in shapes our lives, we are advancing dermatology for every skin story. For more information: www.galderma.com.

References

Galderma. Data on file. SPR.3438.207553

Galderma. Data on file. SPR.3438.207551.

Galderma Data on files – Gematria reports GD-AP-01a-2023, GD-AP-03-2023 and GD-AP-04-2023​

Vidal SI, et al., Defining the Prevalence, Clinical Characteristics, and Demographic Influences on Patients with Sensitive Skin Syndrome: Insights from the Largest Global Survey of Sensitive Skin EADV Congress; 2025; Paris. Poster.

Galderma data on file, RD.SPR.3438.2017106

Galderma. Data on file. SPR.3438.207557

Galderma. Data on file. SPR.3438.207551

Galderma data on file SPR.3438.207557 2, SPR.3438.207558

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20260308270674/en/

Permalink

https://www.aetoswire.com/en/news/54441857

Contacts

 

For further information:

Christian Marcoux, M.Sc.

Chief Communications Officer

christian.marcoux@galderma.com

+41 76 315 26 50

Céline Buguet

Franchises and R&D Communications Director

celine.buguet@galderma.com

+41 76 249 90 87

Viviana Wiewall

Head of U.S. Communications

viviana.wiewall@galderma.com

+1 (786) 451 77 40

Emil Ivanov

Head of Strategy, Investor Relations, and ESG

emil.ivanov@galderma.com

+41 21 642 78 12

Jessica Cohen

Investor Relations and Strategy Director

jessica.cohen@galderma.com

+41 21 642 76 43

 

Kinaxis Announces Amendment to Maximize Size of Normal Course Issuer Bid

 

(BUSINESS WIRE)--Kinaxis® Inc. (“Kinaxis” or the “Company”) (TSX: KXS) today announces that, further to its previously announced intention to maximize the size of its normal course issuer bid (the “NCIB”), it has received approval from the Toronto Stock Exchange (the “TSX”) to amend (the “Amendment”) the NCIB, effective on March 11, 2026 (the “Effective Date”), to increase the maximum number of common shares (the “Shares”) that may be repurchased from 1,403,042, representing 5% of the Company’s issued and outstanding Shares as at October 31, 2025, to 2,799,843, representing 10% of the Company’s “public float” as at October 31, 2025, the maximum amount allowable under the rules of the TSX. No other terms of the NCIB have been amended. The Company has already invested US$54 million under its current NCIB. At the average price paid to date for the Shares under the current NCIB, repurchasing 10% of the Shares would represent an additional investment of approximately US$284 million.

In its February 4, 2026 news release, Kinaxis highlighted the rationale for maximizing the NCIB, with Razat Gaurav, chief executive officer, stating, “There is a fundamental misunderstanding of the opportunities and threats from generative and agentic AI to mission-critical enterprise software, like ours, that solves deeply complex problems and enables highly consequential decisions. As a result, the public markets may not be fully reflecting the underlying value of Kinaxis from time to time. We see value to shareholders in maximizing our ability to buy back Shares under the NCIB structure or other structures that may also be available to Kinaxis. Our substantial moat in industry is built on decades of deep domain knowledge, and our Maestro platform represents the most granular and holistic representation of how underlying supply chains operate. Maestro’s predictions, intelligence and prescriptive decisions are made possible by leveraging a fusion of advanced machine learning, optimization and heuristics. These capabilities are fundamental to supply chain planning and decision making and are enhanced, not replaced, by GenAI, composable agentic AI, and the latest semantic and data architectures to achieve the next generation of supply chain orchestration. We are excited about the possibilities.”

The NCIB, which began on November 12, 2025, and will end no later than November 11, 2026, is being conducted on the open market through the facilities of the TSX and/or alternative Canadian trading systems or by such other means as may be permitted by the applicable securities regulators. Except for block purchases permitted under the rules of the TSX, the number of Shares to be purchased per day under the NCIB will not exceed 14,137, which represents 25% of the average daily trading volume of the Shares on the TSX for the six calendar months ended October 31, 2025 (being 56,549 Shares). Kinaxis previously entered into an automatic share repurchase plan under which its designated broker will repurchase Shares pursuant to the NCIB, and the automatic plan, which will be amended as of the Effective Date to account for the Amendment, will continue to apply to the amended NCIB. The actual number of Shares purchased under the NCIB, including under the automatic plan, the timing of such purchases and the price at which Shares are purchased will depend upon future market conditions and will be determined by management of the Company, subject to applicable law and the rules of the TSX. The automatic plan, which was pre-cleared by the TSX, provides for the potential repurchase of Shares at any time, including when Kinaxis ordinarily would not be active in the market due to it being in a blackout period.

Under the NCIB, to date, Kinaxis has repurchased for cancellation an aggregate of 447,738 Shares (at an average price of C$167.50 per Share).

About Kinaxis

Kinaxis is a global leader in modern supply chain orchestration, powering complex global supply chains and supporting the people who manage them. Our powerful, AI-infused supply chain orchestration platform, Maestro™, combines proprietary technologies and techniques that provide full transparency and agility across the entire supply chain – from multi-year strategic planning to last-mile delivery. We are trusted by renowned global brands to provide the agility and predictability needed to navigate today’s volatility and disruption. For more news and information, please visit kinaxis.com or follow us on LinkedIn.

Cautionary Note and Forward-Looking Information

This press release contains forward-looking information within the meaning of Canadian securities legislation. Forward-looking information relates to future events or the anticipated performance of Kinaxis and reflects management’s expectations or beliefs regarding such future events. In certain cases, statements that contain forward-looking information can be identified by the use of words such as “plans”, “expects”, “is expected”, “budget”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates”, “believes” or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “would”, “might”, or “will be taken”, “occur” or “be achieved” or the negative of these words or comparable terminology. Forward-looking information in this press release includes statements with respect to the potential future purchases by Kinaxis of Shares pursuant to the NCIB and the benefits of the NCIB. By its very nature forward-looking information involves known and unknown risks, uncertainties and other factors that may cause actual performance of Kinaxis to be materially different from any anticipated performance expressed or implied by such forward-looking information.

Forward-looking information is subject to a variety of risks and uncertainties, which could cause actual events or results to differ from those reflected in the forward-looking information, including, without limitation, the risks described under the heading “Risk Factors” in the Company’s annual information form dated March 4, 2026 for its fiscal year ended December 31, 2025 and other risks identified in the Company’s filings with Canadian securities regulators, which filings are available on SEDAR+ at https://www.sedarplus.ca.

The risk factors referred to above are not an exhaustive list of the factors that may affect any of the Company’s forward-looking information. Forward-looking information includes statements about the future and is inherently uncertain, and the Company’s actual achievements or other future events or conditions may differ materially from those reflected in the forward-looking information due to a variety of risks, uncertainties and other factors. The Company’s statements containing forward-looking information are based on the beliefs, expectations, and opinions of management on the date the statements are made, and the Company does not assume any obligation to update such forward-looking information if circumstances or management's beliefs, expectations or opinions should change, other than as required by applicable law. For the reasons set forth above, one should not place undue reliance on forward-looking information.

SOURCE: Kinaxis Inc.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20260309385608/en/

Permalink

https://www.aetoswire.com/en/news/54440719

Contacts

Media Relations

Vanessa Cohen | Kinaxis

vcohen@kinaxis.com

647-822-8540

Investor Relations

Rick Wadsworth | Kinaxis

rwadsworth@kinaxis.com

613-907-7613